



PRESS RELEASE

LFB S.A. increases its capital by 230 million euros

Les Ulis, October 12 2015 – Designed to support the development of the LFB group, the capital increase was voted by LFB S.A.’s Board of Directors on 18th September, and was approved in a general meeting of shareholders on 2nd October. It will be wholly subscribed by the French State which is the sole shareholder of LFB S.A.

The release schedule is based on four successive steps from the first subscription commencing 16th October 2015 for 60 million euros, to the fourth subscription planned for no later than April 2018. At the end of the operation, the authorized capital of LFB S.A. will be 280 million euros (280 000 000 euros), made up of five million six hundred thousand (5 600 000) shares at fifty euros (50 euros) each.

The aim of this capital increase is to support the continuing development of the LFB group for years to come, with the financing of a new manufacturing facility for plasma-derived medicinal products, located in northern France. This “next generation” plant will be operational from 2020 and will allow LFB to triple its global production capacity over the next 10 years. This will also have the added benefit of optimizing production costs, increasing the group’s competitiveness in a highly technological field and meeting the highest global standards, allowing LFB to increase its international sales.

About the LFB group. The LFB group (www.lfb.fr) is a biopharmaceutical company that develops, manufactures and markets medicinal products for the treatment of serious, and often rare, diseases in the fields of Immunology, Haemostasis, Perinatal and Intensive Care. The LFB group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies.

The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group markets its products in more than 40 countries around the world with a global turnover of € 501.9 million in 2014. www.lfb.fr

Contact LFB S.A

Sandrine Charrières – Executive VP Corporate Communications

Phone: +33 (1) 69 82 72 80

email : charrieres@lfb.fr

Media relations contact: Jeanne Bariller

Havas Worldwide

Phone : +33 (6) 15 51 49 40

jeanne.bariller@havasww.com